HowlandECrosswellMD

Clinical Trials

• A Study of Brentuximab Vedotin in Relapsed or Refractory Non-Hodgkin Lymphoma Start of enrollment: 2011 Aug 01

  Completed

  Phase 2

• Efficacy and Safety of Idelalisib (GS-1101) in Combination With Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas Start of enrollment: 2013 Jan 16

  Terminated

  Phase 3

• Efficacy and Safety of Idelalisib (GS-1101) in Combination With Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas Start of enrollment: 2013 Jan 02

  Terminated

  Phase 3

• A Study That Switched Patients From Imatinib to Nilotinib and Then Was Followed by Treatment Cessation Start of enrollment: 2013 Aug 12

  Completed

  Phase 2

• Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacodynamics of Entospletinib in Adults With Relapsed or Refractory Hematologic Malignancies Start of enrollment: 2013 Mar 14

  Terminated

  Phase 2

• BKM120 for Patients With PI3K-activated Tumors Start of enrollment: 2013 Mar 29

  Completed

  Phase 2

• Study of Brentuximab Vedotin Combined With Bendamustine in Patients With Hodgkin Lymphoma Start of enrollment: 2013 Jun 01

  Completed

  Phase 1, Phase 2

• MEK162 for Patients With RAS/RAF/MEK Activated Tumors Start of enrollment: 2013 Oct 10

  Completed

  Phase 2

• Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab in Adults With Previously Untreated Chronic Lymphocytic Leukemia Start of enrollment: 2014 Feb 05

  Terminated

  Phase 3

• BGJ398 for Patients With Tumors With FGFR Genetic Alterations Start of enrollment: 2014 Jul 24

  Terminated

  Phase 2

• Study of Rituximab and Bendamustine With or Without Brentuximab Vedotin for CD30 Positive Diffuse Large B-cell Lymphoma Start of enrollment: 2015 Oct 01

  Terminated

  Phase 2

• 3D Prediction of Patient-Specific Response Start of enrollment: 2018 Jun 11

  Active, not recruiting

• Join now to see all